Mantle Cell Lymphoma Articles

Intriguing Strategies Taking Shape in Mantle Cell Lymphoma
Michael Wang, MD, discusses how the mantle cell lymphoma paradigm is facing a time of exploration, as researchers examine different therapeutic options beyond chemotherapy.
Vorinostat Triplet Elicits High Responses in Newly Diagnosed MCL
The triplet regimen of vorinostat (Zolinza), cladribine, and rituximab (Rituxan) demonstrated an objective response rate of 97% and a complete response rate of 80% in newly diagnosed patients with mantle cell lymphoma.
 
FDA Grants Zanubrutinib Priority Review for Relapsed/Refractory Mantle Cell Lymphoma
The FDA has granted a priority review designation to a new drug application for zanubrutinib for the treatment of patients with mantle cell lymphoma who have received ≥1 prior therapy.
Expert Reflects on Rapidly Evolving Field of MCL
Simon Rule, MD, PhD, discusses the current treatment options in mantle cell lymphoma and explained how anticipated research results could be integrated into the field.
Mantle Cell Lymphoma Options Expand, With CAR-T on the Horizon
Kieron Dunleavy, MD, discusses the current treatment paradigm in mantle call lymphoma and the emerging potential for CAR T-cell therapy.
Frontline Mantle Cell Lymphoma Treatment Must Involve Personalized Approach
Peter Martin, MD, discusses the need for a personalized therapeutic approach in frontline MCL treatment.
Zanubrutinib Continues to Show Encouraging Activity in Relapsed/Refractory MCL
Yuqin Song, MD, PhD, discusses the clinical activity with zanubrutinib in patients with relapsed/refractory mantle cell lymphoma.
Rituximab Regimen Elicits High ORR in Relapsed MCL
Rory McCulloch, MD, discusses the results of a retrospective analysis looking at rituximab, bendamustine, and cytarabine in patients with mantle cell lymphoma who have relapsed on a BTK inhibitor.
Wang Explores Feasibility of CAR T Cells, Personalized Medicine in MCL
Michael Wang, MD, provides insight on recent advances in mantle cell lymphoma as well as research efforts for patients with a high risk of relapse.
Lisocabtagene Maraleucel Shows Promising Response Rates in Relapsed/Refractory MCL
The CAR T-cell therapy lisocabtagene maraleucel elicited a 71% overall response rate as well as a tolerable safety profile in a cohort of patients with relapsed/refractory mantle cell lymphoma.
Publication Bottom Border
Border Publication
x